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ABSTRACT
In this work, the potential for PEGylated gold nanoparticles for use as a platform for stem
cell delivery in treatment of myocardial infarction (MI) is preliminarily investigated.
Cardiovascular disease is currently the leading cause of death worldwide, with majority of
mortality resulting from coronary artery disease and associated MI. The ensuing ischemic
conditions resulting from MI cause substantial heart muscle tissue loss and scarring in the heart.
Adverse tissue remodeling creates a significant loss in heart function that can result in the
formation of cardiac hypertrophy, ventricular dilation and arrythmias. The long-term prognosis of
patients who have suffered MI is poor, with conditions developing into chronic heart failure.
Nanotechnology based stem cell delivery could be used as a novel method to alleviate these
conditions. The heart possesses poor regenerative capacity and the ability to deliver stem cells to
the infarcted myocardium has already been shown to return limited functionality to the heart.
Current methods, although promising have yet to show significant long-term results improving
patient prognosis. Herein we present a novel idea for the use of gold nanoparticles as a means of
directing stem cell delivery in-vivo through targeted and specific delivery with the hopes of
improving patient conditions over current methodologies. The work involved in this THESIS is
related to the establishment of protocols, investigation into particle toxicity, and the development
of a perfusion bioreactor system capable of testing such a platform in-vitro.
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INTRODUCTION
Cardiovascular disease is the leading cause of death in the United States, resulting in

approximately 610,000 deaths per year. Of all cardiovascular conditions, coronary artery disease
(CAD) is considered the biggest killer, causing the death of approximately 365,000 individuals
annually (1). CAD can lead to multiple conditions such as angina and myocardial infarction (MI)
when flow of oxygen-rich blood to a section of the heart is blocked, resulting in the occurrence of
a heart attack. Acute MI is typically caused by thrombus aggregation in one or more of the coronary
arteries preventing blood from circulating in the surrounding tissue. Inadequate blood flow results
in the inability of the tissue to be supplied with oxygen and nutrients, as well as a lack of removal
of waste products, subsequently causing tissue death. While medical interventions such as stenting
or coronary artery bypass grafting surgery can help re-establish blood flow to the affected area,
often some extent of irreversible tissue death has occurred. The restoration of blood flow may also
promote harmful processes in the recovering myocardium, a process referred to as reperfusion
injury. Because of such pathology, death at the cellular and tissue level leads to unwarranted
inflammation and tissue remodeling processes that cause loss of function in the myocardial tissue.
Cardiac remodeling or the reconstruction of myocardial tissue after injury involves a group
of molecular, cellular and interstitial changes that alter both the mechanical and biological function
of the heart. The resultant effects cause changes in geometrical and mechanical properties of the
heart, through alterations in the relative mass, size and geometry as well as changes in cardiac
output. Such resultant pathophysiological changes result in poor patient prognosis and lead to
conditions such as malignant arrythmias and ventricular dysfunction. Such conditions can also
lead to hypertrophy that results in diminished force generation capacity preventing the levels of
perfusion necessary to for all tissues to receive adequate blood supply (2). Many current treatment
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modalities such as those previously mentioned, as well as medication maintenance aim to treat the
incident which has already occurred but do not aim to solve the underlying problem. This is the
problem that regenerative medicine aims to solve. Regenerative medicine through stem cell
therapy aims to provide treatment modalities capable of reversing such adverse cardiac remodeling
processes and return the native structure and function to the heart. Nanotechnology provides a
promising platform to achieving such aims.
1.1

PATHOLOGY OF MI AND THE REPAIR PROCESS IN MYOCARDIAL INJURY:
ADVERSE REMODELING AND REPAIR
Acute Myocardial Infarction is the rapid onset of tissue death due to blockage of blood flow in

a coronary artery. Occlusion of blood flow is the causal condition that leads to MI. This obstruction
typically occurs because of coronary atherosclerosis and prevents oxygen and nutrients from
diffusing to the surrounding tissue. After the onset of MI, ischemia, or the lack of oxygen within
the tissue results in many physiological changes that lead to processes such as inflammation,
cardiomyocyte cell death, ventricular scarring – “remodeling”, and ventricular dilation (3). The
hypoxic environment created by ischemia also causes many changes at the cellular level and can
lead to further effects presenting at both the molecular and tissue system levels through alterations
in cell signaling pathways, and systematic cardiac cell death. Immediate restoration of blood flow
is essential to save the damaged tissue but can result in reperfusion injury to both endothelial cells
and cardiomyocytes. All of the above processes involved in acute MI coalesce to trigger an innate
immune response that is crucial in governing both the immediate inflammatory response as well
as the subsequent recruitment of, activation of, and tissue repair mechanisms by immune system
cells that traffic to the heart (4).
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Figure (1): Overview of the inflammatory process as seen during cardiac repair following MI with
respective phases of inflammation, proliferation, and maturation of scar tissue (5).
The first part of the inflammatory response seen during MI is triggered by alteration in
cardiac cell signaling pathways causing increased cytokine expression known as danger associated
molecular patterns (DAMPs). This enhanced protein expression serves to activate leukocytes and
make them available to respond to the infarct region within the heart. Leukocyte activation and
recruitment acts in parallel with neutrophil and macrophage activation, to mediate a strong
infiltration of immune cells within the tissue. What is intended to be a favorable response can also
be harmful as these repair mechanisms can lead to further tissue damage through the unwarranted
production of reactive oxygen species (ROS), proteases, and lipids (4, 6, 7). This response serves
to liberate the infarcted area of necrotic cells and extracellular matrix (ECM) debris thereby
clearing the way for tissue reconstruction. To prepare for the secondary phase of the immune
response, the intense inflammatory reaction is actively repressed giving way to endogenous
3

proliferative repair mechanisms. During this process, mononuclear cells recruited to the infarct
during the inflammatory phase secrete cytokines and other growth factors which activate
reparative myofibroblast cells which in turn secrete new ECM proteins providing a scaffold upon
which scar tissue can form (6, 8, 9). The beginning of the scarring process or maturation phase is
marked by apoptosis of these fibroblastic repair cells and leads to the generation of collagen-based
scar tissue. As the scar matures, the tissue in the infarct region hardens thereby preventing any
natural tissue regeneration from occurring.

Figure (2): Damage and Remodeling of Left Ventricle as a result of MI. Pathophysiological
change over time include Ventricular Wall Thinning and Heart Dilation leading to long-term
complications of contractile dysfunction and heart failure (3).
These pathogenic changes present clinically as chamber dilation, cardiac hypertrophy and
decreased functional capacity of the heart muscle leading to complications involving ventricular
arrythmias coupled with progressive heart failure (6, 10, 11). The prognosis of such conditions is
poor which raises the question, what can be done in the way of developing new therapies for
treating MI that can prevent functional loss of the tissue and the long-term decline of the patient.

4

1.2

CURRENT MI THERAPIES AND IMPORTANCE OF DELIVERY ROUTES IN
STEM CELL BASED TREATMENT STRATEGIES
Current therapeutic interventions for MI generally involve early reperfusion attempts in order

to salvage tissue and thus prevent further tissue loss. Reperfusion can be achieved through clinical
intervention involving means of using both mechanical and biochemical strategies. Mechanically
invasive procedures such as percutaneous coronary intervention (PCI) involve arterial dilation
followed by the placement of a coronary stent to reestablish blood flow. Fibrinolytic agents can be
used as a biochemical means to dissolve thrombolytic material within the coronary vessels thereby
also reestablishing blood flow (12, 13). Although these procedures have a high efficacy in
preventing sudden mortality, the treatment window in which they can be used is very narrow, and
the ability to prevent long-term complications is poor. Natural healing processes in the adult
myocardium are practically non-existent, with the mature heart possessing a very poor regenerative
capacity with a cellular turnover rate on average of less than one per cent per year (14). With such
limitations, it is crucial that new strategies be developed to treat MI which can provide tissue
regeneration.
The current hope lies in the promises of stem cell-based treatment strategies. Since a critical
limit has been reached for current treatment approaches, a new approach that aims to address the
underlying causes, i.e. regeneration of tissue death that occurred during MI needs to become the
mainstay for MI therapies. In order to guarantee better long-term patient outcomes tissue
regeneration needs to be able to return the heart to a state of pre-MI functionality. Currently many
clinical trials are underway to investigate the delivery of various types of stem cells to the heart
through varying methods.
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The choice of delivery route is especially important as it can influence the main parameters
of that would determine the treatment successful: cell engraftment, retention, survival, integration
with host tissue, and return of functionality. There are currently three main options to consider for
cell delivery routes when administering stem cell therapy to the heart. The first, Intramyocardial
(IM) injection involves direct injection of donor cells into the myocardial tissue. The second
Intracoronary (IC) delivery involves the use of catheter-based approaches and is performed during
PCI. The third, Intravenous (IV) injection involves injection into the systemic vasculature of the
body and relies on the capability of homing mechanisms induced by signaling from the injured
myocardium to deliver the cells to the injured tissue. These approaches have both their advantages
and limitations but none can optimally meet all the necessary requirements for the conditional state
of each patient nor the requirements of each donor cell type (15).These approaches are shown in
shown in Figure (3) as well as the advantages, limitations, and clinical and pre-clinical trial results
of each are discussed in Table (1).

Figure (3): Current major delivery routes during donor cell delivery to the heart post MI. Shown
above as 1. Intramyocardial (IM) encompassing both endocardial, epicardial, and trans-coronary
approaches, 2. Intracoronary (IC) encompassing both anterograde and retrograde approaches, and
3. Intravenous (IV) (15).
6

The first, IM injection typically accompanies a coronary artery bypass grafting (CABG) or
left ventricular assist device (LVAD) implantation procedure and involves the opening of the chest
and thoracic cavity through either a sternotomy or thoracotomy. Due to direct injection, the IM
delivery route enables cells to be delivered more efficiently to areas of limited vascularity with
increased precision (15, 16). This procedure as compared to others allows better visualization of
the infarct zone through direct observation during surgery and gives preferential delivery to larger
cell types (15, 17). Although given more technical feasibility and more direct control over cell
delivery, this method has certain limitations. The necessity to perform this approach in conjunction
with another surgical procedure means that is very expensive as a stand-alone alternative for MI
treatment. Secondly it is highly invasive and can potentially result in complications including the
induction of ventricular arrythmias (18). Even given these disadvantages, this method has been
reported by many sources to be the most efficient means of retaining the greatest number of
implanted cells. In a swine model reported by Hou et al. compared to the other approaches of IC
and IV delivery, the IM approach resulted in a greater amount of the initial cells remaining
transplanted in the heart one hour after cell. Current cells used in this method involve
enzymatically digested cells in suspension, which may have a limited ability to integrate within
host tissue. This can affect the long-term retention and survival even if immediate analysis reveals
promising results.
The second method, the IC delivery route involves the use of a standard balloon catheter
to deliver cells to the myocardium via the coronary arteries. This is the most clinically used
approach as it is less invasive than IM and shows promise for directing cells to the target area in a
manner that results in homogenous cell engraftment (16, 19). Other advantages of this approach
involve the fact that it results in less myocardial injury and results in less long-term complications
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(18). Certain disadvantages do exist with IC administration. Studies have shown that IC
intervention result in lower levels of cell retention after immediate delivery as compared to IM. IC
delivery also appears to contain a threshold to the size of cells that can be delivered before possible
embolization in the smaller coronary arteries can occur with the development of resultant
microvascular infarcts (20-22). Overall this method has many benefits but is limited in the scope
of technological development of catheter technologies (16).
Lastly, IV injection is the least invasive of the three methods and involves injection of the
donor cells into the systemic vasculature. This method in general results in sub-optimal cell
retention and delivery. Studies have reported many cells ending up in unintended tissue locations
such as the lungs, liver and spleen with some studies detecting a 0% efficiency in delivering cells
to the myocardium (20, 23, 24). Engrafting and homing mechanisms of delivered cells to the heart
need to be further elucidated before this approach method can gain more traction clinically. Despite
the fact that it is safe and feasible, a larger database of invariable results needs to be developed in
order to prove that this approach can be considered clinically dependable.
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Table (1): Summary of cell-based delivery approaches used in Stem Cell Therapy.
Delivery Route

Associated
Procedure
Sternotomy or
Thoracotomy
during CABG or
LVAD
Implantation
(25),(26).

Advantages

Drawbacks

Enhanced
targeting of local
tissue damage
(17).
More technically
feasible.
Preferential
delivery of
larger donor cell
types (15).

Highly Invasive
Greater risks for
complications,
including
systematic
embolization,
and cardiac
arrythmias (27).

PCI with
catheter-based
approaches.

Less myocardial
injury, more
homogenous
distribution
during delivery
(18).

Lower
engraftment and
survival of
donor cells
compared to IM
route (29, 30).
Risk of coronary
embolization
during delivery
of larger cell
types i.e.
Mesenchymal
Stem Cells
(MSCs) (31).

Direct injection
into systemic
vasculature.

Least invasive.
Least expensive.
Safe and feasible
(35).

Low Delivery
efficiency ((23,
24, 36, 37))
Must rely on
homing signals
presented by
injured
myocardial
tissue.

Intramyocardial

Intracoronary

Intravenous

Clinical
Outcomes
11.3 %
Engraftment
Efficiency (20)
Mets-analysis,
Sig. ↑ in
ventricular
function over
CABG ctrl (28).
Many studies
show long-term
improvement
during pt.
follow-up.
LVEF increase
3-8% (32).
2.6 %
Engraftment
Efficiency (20).
Sig. ↓ in infarct
size, cardiac
dimensions and
recurrent MI for
cell donor group
vs. placebo
death.
(REPAIR-AMI)
clinical trial (33,
34).
3.2 %
Engraftment
Efficiency (20).
No cell
localization in
heart - PET trial
study (n=3) (24).

The above listed methods have both advantages and disadvantages but cannot objectively meet
the needs of each patient in every scenario. These approaches show promising results but are
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limited in the percentage of cells capable of being delivered to the myocardium. To provide the
potential for successful tissue regeneration, a much more significant effect in cell delivery
platforms needs to be seen. With this objective in mind, the ideal delivery platform needs to be
able to accurately and consistently meet certain criteria. First, donor cells would need be delivered
in a more reproducibly and efficiently consistent manner with low numbers of cells ending up in
other tissue locations. Second, the delivery platform would need to be engineered to promote better
retention, proliferation and health in engrafted cell populations without causing any damage to the
host heart. Lastly, this technique would need to be applicable for delivery of many different types
of donor cells and be able to be utilized in clinical situations of differing critical importance i.e.
patients with acute myocardial infarction to post-MI chronic heart failure (15). The ability to have
a multimodal tool not only capable of providing cell delivery but also encompassing mechanisms
of specific targeting would greatly enhance the potential for the development of life-altering MI
treatments using regenerative medicine. The use of nanoparticles as a delivery platform has been
minimally investigated but has the potential to revolutionize current methods of delivery and
achieve these ideals.
1.3

PHYSICOCHEMICAL INTERACTIONS OF NANOPARTICLES WITH
BIOLOGICAL SYSTEMS AND USE AS DELIVERY PLATFORMS FOR STEM
CELL THERAPY IN THE MYOCARDIUM
In the field of biomedicine, and cardiovascular stem cell engineering, nanoparticles hold much

promise to increase the efficacy of current treatments along with serving as a foundation upon
which new clinical innovations can be built. Nanoparticles are materials that exist on the scale of
1-100 nm that possess many unique physicochemical features that enable them to engage
biological systems and interact with the physiological environment on the micro and nanoscale

10

levels (38, 39). Due to the almost infinite amount of custom property combinations that can be
generated through the attachment of various ligands and bioactive molecules to the surface of
nanoparticles, it is possible to use them for means of modulating parameters such as stem cell
differentiation and proliferation. These unique effects also have the ability to unlock the potential
of nanoparticles as a multimodal tool used in cell delivery platforms capable of imaging and
tracking implanted stem cells within tissues and organs (39). Other material characteristics such
as surface topography, chemical makeup, charge, and shape will all define how a material will
interact within a given system. Cellular interactions also rely heavily on such properties, as
interaction with a material will require dependence on the material’s geometric shape and ligand
presence in order to bind the correct membrane receptors with high affinity (39) In order to utilize
nanomaterials to exploit the many functional properties of stem cells, cellular recognition and
uptake must be maximized.
The nanoparticle characteristics that are the most important in governing these interactions are
chemical composition, shape, ligand presence, roughness, and relative hydrophobicity or
hydrophilicity. At the surface level, these properties will determine how nanoparticles interact with
biomolecules on the cell surface as well as controlling forces related to particle-to-particle
interaction (39, 40). These characteristics will also affect the ionic strength, and electrical double
layer formation of adsorbed ions on the particle surface in biological fluids. Surface charge, ligand
presence, and availability of reactive groups will modulate receptor-ligand binding and the
stability/biodegradability of the particles within tissues, while the effects of electrostatic properties
of the particle may determine the strength of long-range van der Waal interactions with
biomolecules and short-range forces arising from steric effects and biofluid interactions (39, 41,
42).
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Figure (4): Size, shape, surface charge, and biomolecule composition are a few of many
parameters that regulate nanoparticle interaction with stem cells (39).
Nanoparticle properties will affect interaction with biological substrates and the resulting
functional alteration of mechanisms governing both cellular and subcellular particle interactions
and particle uptake (39, 40). These interactions can occur in both a passive and active manner
resulting in both relatively non-specific interaction and highly specific interactions with cellular
components, such as recognition of alterations in cellular signaling patterns. Much complexity in
these interactions arises from intrinsic properties of the particle such as how ligand binding density
on particles would determine particle/cell due to the affinity and binding of cell receptors of
different sizes. i.e. A particle with a high density of ligand present would engage a greater number
of receptor sites and have a higher rate of interaction at greater length scales from the membrane
surface which can be extrapolated to the differing receptors on varying donor cell surfaces (39).
12

Particle size would also affect this, with the correct size and radius of curvature effecting the
particles ability to interact with certain receptors or bind specific ligands. Interactions at this level
are more dynamic due to the fluidity and thermodynamic properties – temperature, specific Heat
capacity, etc. of the cell membrane. The cell membrane is a compliant and non-rigid structure that
can deform upon both environmental and physical cues leading to an even more complex set of
interactions governing particle uptake. Since cells are not passive entities, they have the capability
to secrete soluble factors, proteins and other biological molecules in response to environmental
stimuli. Such stimuli can be activated through interaction with nanoparticles, enabling the use of
particles as tools to modify the physiological environment post transplantation. In relation to donor
stem cells, these interactions would greatly depend on the stage of differentiation, the presence of
growth factors in the biological fluid, as well as current cell proteome based on the relative health
and cell state (39).
Stem cell migration to a damaged are of tissue, known as the homing mechanism is an
important area of stem cell research. It appears that human mesenchymal stem cells have the
capability to communicate with other cells in the body and respond to damaged tissues in response
to cellular damage signals (43, 44) Tailoring these properties to enhance the attachment of specific
ligands capable of recognizing DAMP signals in the infarcted myocardium would greatly increase
the potential of using nanoparticles as delivery platforms capable of targeting signals expressed by
the infarcted myocardium. Conjugating nanoparticles to the surface of cell through receptor-ligand
binding would enable this type of platform to be utilized in cell delivery and greatly enhance the
homing capabilities of implanted or injected donor cells.
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1.4

HOLISTIC PROJECT OVERVIEW
The addition of regenerative stem cells to the damaged heart has the potential to induce a
variety of cardioprotective mechanisms through a variety of different means. For example, the
administration of bone-marrow derived stem cells the heart has been shown to release soluble
factors that mediate cardiac repair, neovascularization, and cytoprotection to stimulate
endogenous cardiogenic progenitor activity and new cardiomyocyte formation and to increase
capillary density and improve blood flow recovery after ischemia (45-47). In conjunction with
the objectives outlined in section 1.2, other important challenges that will need to be addressed
are the optimum treatment window to when the cells need to be optimally delivered, as well
how to ensure localization and function within the infarcted area. The important objectives are
listed below:
1) Reproducible and efficient delivery with low numbers of cells ending up in other tissue
locations.
2) Platform capable of promoting better retention, proliferation and health in engrafted
cell populations over current methods without causing any damage to the host heart.
3) Application across many different types of donor cells.
4) Determination of optimal treatment time to deliver stem cells.
5) Ensure localization and function of delivered donor cells within the infarcted area.
This work proposes the design of a multifunctional nanoparticle capable of delivery
conjugated stem cells to the infarcted myocardium. The mechanism of action to be presented
by the nanoparticle would be capable attaching donor cells through ligand receptor interaction
and recognizing the expression of danger signals from the infarcted myocardium, thereby
acting as a trafficking medium to deliver the stem cells to the heart down this natural
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biochemical signaling gradient. Certain targeting biomolecules capable of recognizing DAMPs
would also be conjugated to the particle surface enhancing the homing abilities of the delivery
system through chemotactic gradients to ensure a more reproducible and efficient delivery
method. Through means of directing attached donor stem cells to traffic through circulation
and arrive in the infarcted myocardium is an exemplary approach involving novel active
targeting mechanisms and holds the potential to revolutionize stem cell treatment for MI.

Figure (5): Schematic diagram of particle system design. Substrate X represents cardiac signaling
target expressed in the ischemic myocardium. Substrate Y represents the stem cell receptor capable
of recognizing conjugated ligands on the particle. Figure by Dr. Morten Jensen – not drawn to
scale.
My thesis project consists of a subset of preliminary work aimed at laying out protocols and
establishing methods towards developing the endpoint of a fully-functional particle delivery
system. To initially determine the feasibility and potential for this platform, the cytotoxic effects
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of the particles on native heart tissue must be understood and a model for replicating ischemia and
reperfusion in-vitro needs to be developed so that in-vitro testing can replicate conditions that
would be encountered by the particle delivery platform in-vivo. My thesis work is aimed at
accomplishing these goals. With the aim of addressing objective #2 listed above, it is important to
first study the cytotoxic effects the desired nanoparticles may have on the cells they are to be
interacting with. This point accompanies the first specific aim (SA) of my thesis: determination of
factors such as nanoparticle size, concentration and time of interaction that may have negative
effects on cell viability. The second specific aim is a related to a portion of work in the
development of a bioreactor system capable of culturing cardiac cells with the objectives of
simulating ischemia and reperfusion in an in-vitro. The second specific aim of my thesis involves
the development of a culture platform for incorporating the cells into the bioreactor system. Due
to the multi-collaborative nature of my research group, specific aim #2 involved the development
of a novel cellulosic biocomposite polymer for use in the bioreactor system with which results in
its efficacy as a culture platform will be discussed in this work.
2

SPECIFIC AIM 1: SYNTHESIS, CHARACTERIZATION AND VIABILITY
ASSESSMENT OF NANOPARTICLES ON CARDIOMYOCYTES
The consideration of stealth properties is important when selecting a nanoparticle for use in

any kind of drug, cell or material payload delivery system in vivo. Stealth properties enable the
particle to avoid immune detection and rejection. The use of Poly(ethylene glycol) or PEG has
been shown to exert shielding effects when conjugated to nanoparticles by shielding them from
interaction with proteins in biological media. This effect provides not only stability but stealth
properties and decreases antibody detection of potential antigens adsorbed on the particle surface
i.e. the reduction in opsonization and associated uptake by phagocytes (39, 48). Functionalization
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of nanoparticles with PEG has also been shown to increase the blood half-life and biodistribution
of such materials in circulation (39, 49, 50). PEG chain attachment can enhance the hydrophilicity
of the particle surface and impart other significant bioactive qualities by allowing further covalent
linkage of other biomolecules to the ends of PEG polymer chains. PEG is known to interact
favorably with gold nanoparticles by attachment through thiol linkages. The terminal ends of PEG
chains can attach to gold nanoparticles through Au-S covalent bonding with a high binding energy
of 418 kJ/mol (51). This favorable interaction increases steric hindrance within colloidal systems
and decreases particle-particle interaction. For use in biological media, it is important to have less
interparticle interaction as it can result in the formation of unstable aggregates and greatly
influence unwarranted protein interaction and cellular uptake. Gold nanoparticles (GNPs) have
already been established as attractive candidates for use in in-vivo applications such as gene and
drug delivery, biosensing, imaging contrast agents, photothermal therapy and many more (39, 52,
53). Furthermore, gold nanoparticles can be synthesized in a high yield and highly reproducible
manner with good control over size and shape characteristics. This allows the user to easily develop
particle systems with narrow margins of error to achieve a specific goal. Due to these unique
physicochemical characteristics, we selected PEGylated gold nanoparticles (PEG-GNPs) as our
particle system of choice for use as a stem cell delivery platform. When engineering PEG particles
with certain properties for use in vivo, it is important to examine their biological behavior and
determine any potential cytotoxicological effects they may have on their intended target.
Therefore, we have chosen to begin the investigation for their use in our intended application with
a toxicity study in which we aim to determine, size, concentration, and time dependent toxic effects
that may come into play with PEG-GNP interaction with cardiac cells.
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3

MATERIALS AND METHODS FOR SPECIFIC AIM 1

3.1 MATERIALS/CHEMICALS FOR GNP SYNTHESIS AND CELL CULTURE
Hydrogen tetrachloroaurate

trihydrate (Cholorauric acid – HauCl4 • 3H2O, 99.9%) was

purchased from STREM Chemicals (Newburyport, MA). Trisodium citrate dihydrate (C6H9Na3O9
• 2H2O, >99.5%), Poly(ethylene glycol) methyl ether thiol (CH3O(C2H4O)nC2H4SH, Mn = 2000
Da), and tannic Acid (C76H52O46) were purchased from Sigma Aldrich (St. Louis, MO). These
chemicals were used as synthesized without further purification or modification. Carbon-coated
Transmission Electron Microscopy grids (300 mesh, 63 μm grid hole size), were purchased from
Ted Pella Inc. (Redding, CA). All glassware and reaction vessels used in synthesis and PEGylation
reactions involving the GNPs were first rinsed with ultrapure water (18.2 MΩ-cm resistivity) then
rinsed vigorously with acetone (99.7%), followed by 3x rinsing with the same ultrapure water.
Both ultrapure water and acetone were purchased from MilliporeSigma (Burlington, MA). The
same ultrapure water was used in preparation of the GNP solutions and other aqueous reagents.
UV-Vis characterization was performed using a NanoDrop 2000c Spectrophotometer from
Thermofisher (Waltham, MA). DLS and zeta potential measurements (ζ-pot.) were performed
using a Malvern Zetasizer Nano ZS system (Almelo, Netherlands). TEM images were collected
using a JEOL JEM-1011 microscope (Tokyo, Japan) operated at 100 kV, with an AMT V602
camera and image capture engine software (Woburn, MA). Images were further post-processed
using ImageJ.
For NRCM culture, media along with other cell culture ingredients were purchased from
Thermofisher. Media was formulated from stock Media 199 and supplemented with 1% v/v of
Penicillin/Streptomycin and 0.2% v/v Gentamicin/Amphotericin B. For viability assessment, the
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CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) was used from Promega
(Madison, WI).
For cell fixation and permeabilization, paraformaldehyde 4% in PBS, Triton X-100, and
Bovine

Serum

Albumin

(BSA)

were

purchased

from

VWR

(Radnor,

PA).

For

immunocytochemistry and immunofluorescent imaging, primary and secondary antibodies antisarcomeric alpha actinin, and AlexaFluor® 488 conjugated goat anti-mouse IgG were purchased
from Abcam (Cambridge, United Kingdom). (Abcam: ab9465), and (Abcam ab150113)
respectively. DAPI was purchased from Thermofisher. Immunofluorescent imaging and analysis
was carried out using an Axio Imager M.1 Upright Fluorescence Microscope from Zeiss
(Oberkochen, Germany) with included Axiovision image analysis software.
3.2

METHODS FOR SYNTHESIS, PEGYLATION, AND CHARACTERIZATION
In this study, three sizes of GNPs were synthesized in order to investigate the effects size may

have on cellular toxicity. The protocol used in this study to synthesize the two larger sized GNP
samples ~ 18, and 25 nm was adopted from (54) and involved varying the molar ratios of trisodium
citrate to HAuCl4 to produce GNPs of different sized diameters. For this protocol, a gold salt stock
solution of 25 mM was first prepared by dissolving HAuCl4 in 10 mL of ultrapure water. Next,
trisodium citrate solutions were created by dissolving this chemical in 100 mL ultrapure water at
molar concentrations of 1.6 mM, and 3.4 mM. Each solution was kept under constant pressure in
an Erlenmeyer flask and heated to 90C under vigorous stirring conditions. At this point, an aliquot
of the gold salt stock solution was injected into the reaction mixture resulting in a final HAuCl 4
reaction concentration of 0.800 mM. After addition of the HAuCl4, the resultant molar ratios of
Trisodium citrate: HAuCl4 were 2, and 4.25, producing particles of size ~ 25, and 18 nm
respectively. The reaction was allowed to proceed for 10 min, or until a deep ruby-red color was
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noted in the reaction flask, indicative of the presence of citrate-stabilized GNPs. This reaction
method of first heating the trisodium citrate solution followed by injection of the gold salt stock
solution utilized the Inverse Turkevich Method (55), and was experimentally determined to be
quicker, creating smaller more uniform particles, and allowed for reaction conditions that provided
better size and shape control over during our synthesis procedure.
To synthesize the smallest size particle, a protocol from (56) was adapted with the utilization
of tannic acid along with sodium citrate as a co-stabilization agent. The use of tannic acid allowed
the production of small ~ 5 nm diameter particles with a narrow size distribution. The Inverse
Turkevich Method was also utilized for this synthesis procedure. First a 100 mL solution of 2.2
mM sodium citrate was heated to 90° C under constant pressure and vigorous stirring conditions.
Next, when the solution had reached 90° C, 1.3 mL of a stock solution of tannic acid (2.5 mM)
dissolved in ultrapure water was added to the reaction fixture, followed by injection of the gold
salt stock solution, final reaction concentration 0.167 mM. Color change was noted much more
rapidly here, with the final product exhibiting a light brown – orange color solution indicative of
very small GNPs (56).

Figure (6): Color change during GNP synthesis reactions. Left: 18 and 25 nm GNP synthesis.
Right: 5 nm GNP synthesis “Adopted” from Ref. (54).
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Post synthesis, the citrate-gold nanoparticles were allowed to cool to room temperature and
then filtered through a 0.2 μm cellulose acetate membrane. UV-Vis measurements were performed
to determine absorbance values. PEGylation reactions via ligand exchange were then carried out
at room temperature in an Erlenmeyer flask by adding thiolated PEG (Mn = 2000 Da) for a final
suspension volume of 0.05% w/v. This mixture was allowed to react for 2 hrs. at room temperature
under vigorous stirring conditions. Subsequent absorbance measurements were conducted with a
path length of 10 mm, and then particles (18 and 25 nm) were washed 2x to remove excess citrate
and PEG through centrifugation using an Avanti J-25 centrifuge, Beckman Coulter (Brea, CA),
operated at 12,000 and 10,000 RCF respectively followed by re-suspension in autoclaved ultrapure
water. In order to sediment the PEGylated 5 nm particles during the washing process a Beckman
XL-90 ultracentrifuge was used with a Type-90 Ti rotor operated at 150,000 RCF. Final particle
suspensions were re-concentrated to 0.600 μM, and sterile filtered through a 0.2 μm membrane
under the cell culture hood.
For TEM Analysis, nanoparticle suspensions were first sonicated in a sonication bath for
2 min and then checked for abs. value. Suspensions were then diluted until a relative abs value of
0.2 was achieved. Particles were then sonicated for a further 2 min, and then pipetted onto carboncoated TEM grids. These grids were allowed to air dry overnight under a vent hood. TEM Images
were further post-processed using ImageJ, and particle diameters were calculated using image
thresholding, and the ImageJ particle size analysis plug-in. For image analysis, pixel aspect ratios
(pixels/nm) of 7.2, 2.4, and 0.6 for samples GNP-5 nm, GNP-18 nm, and GNP-25 nm respectively.
For DLS and zeta-potential measurements, particles were measured prior to the washing
procedure. Cuvettes were thoroughly rinsed with both 70% ethanol and ultrapure water and
allowed to dry in an oven at 100° C for 1 hr. prior to use to ensure the presence of no contaminants.
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Measurements were conducted at 25° C, with automated scan runs based on measurement inputs.
It should be noted due to the concentration of the as-synthesized 5 nm GNPs, reliable
measurements via this modality were unable to be attained.
3.3

METHODS FOR HARVEST, CULTURE, VIABILITY ASSESSMENT, AND
IMMUNOFLUORESCENT IMAGING OF CARDIOMYOCYTES.
The animal use protocol used in this study was approved by the University of Arkansas,

Institutional Animal Use & Care Committee (# 17061). Cardiomyocytes were isolated from 1-3day old Sprague-Dawley rat pups. The rat pups were first euthanized by means of decapitation
followed by excision of the heart tissue. The heart tissue was then further processed by sequential
enzymatic digestion, and cardiomyocytes were isolated from a non-homogenous cell mixture by
means of centrifugation and differential pre-plating steps. The final cell suspension was plated into
96-well plates at seeding densities of 80,000 cells/well and cultured in 10% FBS Media 199 for
the first 3 days in culture later to be replaced by 2% FBS Media 199 for the subsequent culture and
experiments. Cells were cultured in a humidified incubator at 37° C, and 5% CO2. 96-well plates
were pre-coated with collagen type I, at a density of 10 ug/cm2. On Day 2 post-isolation, nonviable cells were removed from cell populations by washing with PBS, followed by media change
of 10% FBS. On Day 3 post-isolation media was changed to 2% FBS, followed by one further
change at day 5 at which experiments were begun.
For viability assessments, cells at day 5 of culture were inoculated with the particles over a
range of concentrations decreasing as a factor of log10 from 100μM – 1pM, and colorimetric
measurements were taken at time points of 0,2,5, and 10 days. The MTS assay, (colorimetric
assessment) involved adding the MTS dye, 25 μL per well to the cell suspension at these time
points and recording the resultant color change after a 4-hr. incubation time at 37° C, and 5% CO2.
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This involved the reduction of the MTS tetrazolium salt compound by viable cells to create a
colored formazan dye product, at which absorbance with a Biotek Synergy HT 96-well plate reader
(Winooski, VT) was recorded at 490 nm. Magnitude of absorbance was directly correlated to
number of viable cells within a given suspension.
For immunocytochemistry and immunofluorescent imaging, cells were first cultured on
collagen coated glass coverslips (10 µg/cm2) and then fixed using 4% paraformaldehyde in PBS,
followed by addition of a permeabilization and blocking buffer consisting of 2% FBS v/v, 2%
BSA v/v, and 0.1% v/v of Triton X-100 in order to prevent non-specific binding of antibodies.
Cells were treated with primary antibody anti-sarcomeric alpha-actinin at a dilution of 250x
followed by secondary antibody and AlexaFluor® 488 conjugated goat anti-mouse IgG at a
dilution of 200x. Cells were cross-stained with DAPI at a dilution of 5000x in order to determine
homogeneity of myocytes with the population. After cell fixation, coverslips were mounted on
glass slides, and immunofluorescent Imaging was carried out using a Zeiss Imager M.1 microscope
at 63x magnification with fluorescent filters. Images were captured using the Zeiss Axiovision
software.
4

RESULTS: CHARACTERIZATION OF NANOPARTICLES
Nanoparticles were characterized using four primary modalities. (1) Transmission Electron

Microscopy (TEM) was used to assess nanoparticle size and relative aggregation state for both pre
and post PEGylation states (3 images each). For TEM analysis, collected images revealed
significant aggregation of citrate capped GNPs. See Figure (7) A-C for 5,18, and 25 nm particles
as compared to even distribution of particles on TEM grids for D-F respectively. As can be seen
in comparison between the two images for each set of particles, PEGylation results in increased

23

steric hindrance between gold cores representing a more even distribution of particles in solution
phase.

A

B

C

D

E

F

Figure (7): TEM characterization of GNPs. Images A-C show a pre-PEGylated state of GNPs
with weak capping agent citrate of 5, 18, and 25 nm respectively. The corresponding images D-F
show PEGylated GNPs for each particle size. PEG was conjugated to the GNP surface via ligand
exchange through via thiol linkage at a concentration of 0.05% w/v.
TEM images were post processed and diameter was calculated using ImageJ. ImageJ was
used to determine if TEM imaging can detect significant size differences between particles given
PEGylation state, i.e. was TEM capable of detecting ligand presence on the surface of the particles.
The calculated particles sizes are shown in Table (2), with respective standard deviations of 0.80,
1.14, and 3.16 nm for the 5, 18, and 25 nm citrate-GNPs. After PEGylation, the standard deviation
for each respective particle size was determined to be 1.21, 1.4, and 3.65 nm. The standard
deviation was determined to be higher but not necessarily significant for PEGylated GNPs.
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TEM Average Size
Sample Name

Pre-PEG

Post-PEG

# Observations

Size (nm)

# Observations

Size (nm)

5 nm GNP

999

4.68

4318

4.58

18 nm GNP

264

17.09

15179

18.21

25 nm GNP

162

25.14

3347

24.67

Figure (8): Calculated diameters of GNP cores by TEM by pre and post PEGylation state.
Comparative analysis of PEGylation state size for TEM was performed using a two-tailed
student’s t-test assuming equal variance with a sig. level of α = 0.05. The results of this test are
shown in Figure (9) with only the 5 nm sample revealing significant differences by PEGylayion
state, p = 0.010.
TEM GNP Size by PEGylation State
30

25

Diameter (nm)

20

GNP

15

GNP-PEG
10

p < 0.05

5

0

5 nm GNP

18 nm GNP

25 nm GNP

Figure (9): Comparison of TEM calculated particle sizes by PEGylation state. The 5 nm sample
revealed a sig. difference with p = 0.010.
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The (2) and (3) modalities used during particle characterization were primarily used to
validate the presence of PEG binding to the particle surface. The first technique used – Dynamic
Light Scattering or DLS is a method used to measure the geometrical structure, Brownian motion,
and hydrodynamic diameter of particles in solution phase (57). Brownian motion is the diffusion
of particles within a solution caused by the bombardment of the solvent molecules that surround
them. DLS directly measures the speed (D) or translational diffusion coefficient at which particles
are diffusing in a solution by detection of the rate at which the intensity of light fluctuates as a
result of the scattering by the particles. The hydrodynamic diameter of the particle can be
extrapolated from this data by the application of Stokes-Einstein relationship, where d(H) is the
hydrodynamic diameter of the particle, k is Boltzmann’s constant, T is the temperature, and η is
the viscosity of the solution. This relationship is shown below (58).
Equation (1):
𝑑(𝐻) =

𝑘𝑇
3𝜋𝜂𝐷

Data for the calculated hydrodynamic diameters is indicated in Table (2) below and
resulted in pre-PEG calculated sizes of 18.49 +/- 0.09 nm and 25.85 +/- 0.49 nm for the 18, and
25 nm GNP samples respectively. These tests were performed in triplicate with as synthesized
samples diluted to a concentration of 0.300 mM, and the 5 nm particles used as synthesized at
0.167 mM. The data is presented as SEM +/- SD. It should be noted that for the 5 nm GNP sample,
the concentration of was below the threshold needed for reliable measurements.
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Table (2): PEGylation state resulted in size and zeta-potential differences assessed by paired
student’s t-test. For 18 nm, the difference in size and zeta potential between pre-PEG and
PEGylated GNPs resulted in p < 0.001 for both cases, for the 25 nm particles, p < 0.01 for size,
and p <0.001 for seta potential. DLS measurements were performed in triplicate, with n = 10 for
zeta-potential. This validates the PEGylation protocol used in this study was effective.

Zeta-potential measurements were also another effective means to characterize and
validate the presence of PEG on the particle surface. Zeta-potential in theory can be described as
a physical property which is exhibited by any particle in a colloidal suspension system. Zeta
potential is characterized as the potential at the boundary between where ions are strongly bound
to a particle and the slipping plane where particles leave the immediate attraction region
surrounding the particle and enter the bulk dispersant.

27

Figure (10): Schematic representation of zeta potential (60).
The effects are readily noted for the zeta measurements for both the 18 nm and 25 nm
particle samples, with PEGylation decreasing each significantly and validating the PEG
attachment on the surface of the particle. The reported decrease in zeta potential to ~ -4 mV is
similar to previous reported results ~ -2 mV for both 10 and 30 nm PEG coated GNPs (64). It
should be noted that for the 5 nm GNP sample, the concentration of was below the threshold
needed for reliable measurements.
The last technique used to characterize nanoparticles was UV-Visual Spectrum
Spectrophotometric absorbance. This relationship can be explained according to the Beer-Lambert
Law below:
Equation (2):
A = εlC
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For this relationship, A represents absorbance, where ε is the molar absorptivity coefficient,
l is the characteristic path length, and C is the particle concentration. In Figure () the effects of
particle size can be seen relative to the absorbance spectrum. This data has been normalized for
each particle species as to where the max. absorbance value for each is set to 1. It can be seen that
with increasing particle size the wavelength of max absorbance shifts to the right or “red-shifts”
closer to the infrared region of the light spectrum with 5 nm citrate GNPs possessing a max
wavelength of 509 nm, 18 nm particles max abs. at 517 nm, and 25 nm max abs. at 524 nm.

Figure (11): Absorption spectrum of citrate-capped GNPs as synthesized prior to PEGylation.
Data has been normalized to reflect the max. abs of each particle species to be equal to 1.
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Figure (12): Shifts in maximum absorbance wavelength for each particle species can be seen for
the PEG-functionalized particles. Data has been normalized to reflect the maximum absorbance of
each particle species to be equal to 1.
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5
5.1

RESULTS OF VIABILITY ASSAY
CONCENTRATION EFFECTS ON CELL VIABILITY
Each dataset was checked for normality of distribution by the Shapiro-Wilk test at a

significance level of α = 0.05, and non-normal distributions are indicated by red boxes on each
respective box plot figure. Both, parametric and non-parametric statistical methods were used to
analyze data as all data contained at least one dataset that expressed a non-normal distribution.
This was considered a possible source of variation in magnitude of observed effects. In order to
determine overall trends of data in relation to size, concentration and time dependence effects, all
data points were averaged for two of the factors and plotted against the third. The effects were
analyzed parametrically via one-way ANOVA followed by Tukey’s HSD post-hoc to elicit
statistical significance between pairwise comparisons. The effects were analyzed nonparametrically via one-way Kruskal-Wallis Test followed by Dunn’s post-hoc without correction
to elicit statistical significance between pairwise comparisons. Both tests were conducted at a
significance level of α = 0.05. For pair-wise comparison post-hoc charts listed below, * = p < 0.05,
** = p < 0.01, *** = p < 0.001.
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Abs. "Normalized to Ctrl"

Data Normality by Concentration for all
Times and Sizes
3.000
2.500
2.000
1.500
1.000
0.500
0.000
Ctrl

100 uM 10 uM 1 uM 100 nM 10 nM 1 nM 100 pM 10 pM 1 pM
Concentration

Figure (13): Box plot for normality assessment of viability data: all datapoints for size and time
averaged for each concentration. Interquartile, and max. and min. values represented by tick marks
and color changes in plotted boxes. Red boxes represent data sets with non-normal distributions.
The normality assessment for Concentration effects, Figure (13) revealed three non-normal
datasets at concentrations of 100 uM, 100 nM, and 1 nM given p values of p < 0.05, p < 0.01, and
p< 0.01 respectively. Cell viability determined by concentration effects is plotted in Figure (14).
Results showed a concentration dependent effect in which all cells inoculated at a given
concentration exhibited higher viability than the ctrl – cells without particles. The data follows a
normal distribution, in which the highest, and lowest concentrations of PEG-GNPs have the least
pronounced effects on cell viability. 1 nM exhibits the best cell viability and is most significantly
different from the ctrl and 100 uM concentrations for both parametric and non-parametric analysis
at p < 0.001. As can be seen in comparison of the two pairwise comparison charts – Figures (14),
and (15) the non-parametric approach of using Kruskal Wallis followed by Dunn’s post-hoc
revealed more sensitivity in detecting significant differences as the effects are much more
pronounced as can be seen for a greater number of comparisons. Data is reported as mean +/- SEM.
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Viability by Concentration for all Times and Sizes
Abs. "Normalized to Ctrl"

1.250
1.200
1.150
1.100
1.050
1.000
0.950
0.900

Ctrl 100 uM 10 uM 1 uM 100 nM 10 nM 1 nM 100 pM 10 pM 1 pM

Concentration

Figure (14): Viability averaged for all times t = 0, 2, 5, and 10-days, and sizes 5, 18, and 25 nm
plotted versus concentration. Both parametric and non-parametric methods were used to assess
statistical differences. Consult Figures (15) and (16) respectively.

Figure (15): Significant difference for Figure (14) datasets as assessed by parametric methods:
one-way ANOVA and Tukey’s HSD post-hoc. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure (16): Significant difference for Figure (14) datasets as assessed by non-parametric metric
methods: Kruskal-Wallis, Dunn’s post-hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001.
5.2

SIZE EFFECTS ON CELL VIABILITY

Abs. "Normalized to Ctrl"

Data Normality by Size for all Times
and Concentrations
3.000
2.500
2.000
1.500

1.000
0.500
0.000
Ctrl

5 nm

18 nm

25 nm

Size

Figure (17): Box plot for normality assessment of viability data: all datapoints for time and
concentration averaged for each size. Interquartile, and max. and min. values represented by tick
marks and color changes in plotted boxes. Red boxes represent data sets with non-normal
distributions.
The normality assessment for Size effects, Figure (17) revealed three non-normal datasets
for all particle sizes for values of p < 0.001, p < 0.001, and p< 0.01 respectively. Ctrl specifies
viability for cells cultured without nanoparticles averaged across all timepoints. Data for particle
sizes has been normalized relative to ctrl. Cell viability determined by size effects is plotted in
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Figure (15). Results showed a size dependent effect with increasing cell viability as a result of
nanoparticle size. PEG-GNPs with a 25 nm gold core promoted the best viability, with all particle
sizes exhibiting better viability than the ctrl group. The 25 nm particles showed significantly better
viability than the ctrl group and 5 nm particles with p < 0.001 for both parametric and nonparametric analysis. As can be seen in the post-hoc pairwise comparison charts – Figures (19) and
(20), the effects when analyzed non-parametrically are more pronounced as the 18 nm group shows
a significant increase in cell viability over the ctrl and 5 nm groups with p < 0.001 for both as
compared to parametric analysis where p < 0.01. Data is reported as mean +/- SEM.

Viability by Size for all Times and Concentrations
Abs. "Normalized to Ctrl"

1.250
1.200
1.150
1.100
1.050
1.000
0.950
0.900
Ctrl

5 nm

18 nm

25 nm

Size

Figure (18): Viability averaged for all times t = 0, 2, 5, and 10-days, and concentrations, log10
decreasing from 100 µM – 1 pM plotted versus concentration. Both parametric and non-parametric
methods were used to assess statistical differences. Consult Figures (19) and (20) respectively.

Figure (19): Significant difference for Figure (18) datasets as assessed by parametric methods:
one-way ANOVA and Tukey’s HSD post-hoc. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure (20): Significant difference for Figure (18) datasets as assessed by non-parametric metric
methods: Kruskal-Wallis, Dunn’s post-hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001.
5.3

TIME EFFECTS ON CELL VIABILITY

Data Normality by Time for all Sizes
and Concentrations
3.000
2.500

Abs.

2.000
1.500
1.000

0.500
0.000
0 day

2-day

5-day

10-day

Time

Figure (21): Box plot for normality assessment of viability data: all datapoints for size and
concentration averaged for each time. Interquartile, and max. and min. values represented by tick
marks and color changes in plotted boxes. Red boxes represent data sets with non-normal
distributions.
The normality assessment for Time effects, Figure (21) revealed three non-normal datasets
for all particle sizes for measurement times of 0-day, 5-day, and 10-day with p < 0.001 for all. Cell
viability determined by time effects is plotted in Figure (22). Results showed a variable time
dependent effect with cell viability decreased cell viability at 2-day time point, only to recover at
5-day and then decrease again at 10-day. Data in this case is averaged for all particle sizes and
concentrations, including ctrl – no particles, at each time pt. As can be seen in the post-hoc pairwise
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comparison charts – Figures (23) and (24), the effects when analyzed non-parametrically are more
pronounced as the 2-day group is significantly less than viability at 0-day for p < 0.05 when nonsignificant for parametric analysis. Also, the 10-day group shows significantly less viability
compared to the 2-day group at p < 0.001 but is only significant at p < 0.01 when determined by
parametric analysis where p < 0.01. Data is reported as mean +/- SEM.

Viability by Time for all Sizes and Concentrations
1.250
1.200

Abs.

1.150
1.100
1.050
1.000
0.950
0.900
0 day

2-day

5-day

10-day

Time at Measurement

Figure (22): Viability averaged for all sizes 5, 18, and 25 nm, and concentrations, log10 decreasing
from 100 µM – 1 pM plotted versus concentration. Both parametric and non-parametric methods
were used to assess statistical differences. Consult Figures (23) and (24) respectively.

Figure (23): Significant difference for Figure (22) datasets as assessed by parametric methods:
one-way ANOVA and Tukey’s HSD post-hoc. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure (24): Significant difference for Figure (22) datasets as assessed by non-parametric metric
methods: Kruskal-Wallis, Dunn’s post-hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001.
6

SPECIFIC AIM 2: FABRICATION OF SCAFFOLD FOR CULTURE OF
CARDIOMYOCYTES WITHIN BIORECATOR SYSTEM
Due to the multi-collaborative nature of our research group and faculty, it was decided that

during the scaffold design and fabrication process a novel bio-composite polymeric material would
be developed for means of supporting cardiomyocyte cell culture within the perfusion chamber of
the bioreactor system. The utilization of mechanically strong cellulose nanocrystals would serve
as a reinforcer material for a synthetic polymer blend scaffold approach. The method of spin
coating to produce polymer films of micron sized thickness would first be utilized to develop the
correct technology governing solvent-polymer and solvent-CNC suspension properties. This
technology then will be transitioned into the application of Rotary Jet Spinning (RJS), for the
development of a porous nanofiber mesh network as both approaches utilize the rapid evaporation
of the solvent material to produce either a polymeric thin film or nanosized polymer fibers
respectively. It should be noted that in this work that technological transition into fibrous scaffold
production is included in future directions.
The first objective in the fabrication procedure was polymer selection. Polycaprolactone (PCL)
was selected as the polymeric material of choice as it is an FDA approved polymer for use within
the human body and has been used previously in the development of materials for cardiovascular
tissue engineering (67-69). Cellulose Nanocrystals (CNCs) were selected as a reinforcer material
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due to their unique physicochemical properties and ability to be used as a biomedical material.
CNCs possess remarkable physicochemical properties such as unique surface chemistry,
extremely high mechanical strength, as well as excellent biological properties of biocompatibility,
biodegradability, and low toxicity (70). The important aspects of CNC for use in our application
good biocompatibility and high mechanical strength, both of which are necessary pre-requisites
for cardiomyocyte culture. The force generated by cyclically contracting cardiomyocytes can
introduce internal stress within a material substrate over time. The use of CNCs as a reinforcer
aims to alleviate this through stress redistribution within the polymer matrix thereby decreasing
the long-term wear and tear on the film.
The films developed in this project were oxygen plasma and imprinted with a nanodimensioned groove-ridge pattern. These surface treatments were done to create surface conditions
appropriate for promoting tissue development similar to what would occur in vivo. Material
characterization was performed using the modalities, of Goniometry, Scanning Confocal Light
Microscopy, and Scanning Electron Microscopy SEM. Two study endpoints for film development
were used to characterize the responses of cell growth and alignment. (1) response of cell growth
and function to increasing concentrations of CNC in polymer matrix. Final CNC weight/volume
% concentrations of (0, 0.01, 0.02, 0.05, and 0.10) were used. (2) Response of cell alignment based
on patterning condition. Films were either patterned with a flat PDMS stamp or a nanopatterned
PDMS stamp introducing nanosized ridge-groove indentations on the material surface. Cell
Viability cell functionality were characterized in response to these conditions.
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6.1

MATERIALS AND METHODS FOR SPECIFIC AIM 2

6.1.1 CNC ISOLATION
A suspension of (CNC) was prepared by hydrolyzing micro-crystalline cellulose powder
(MCC) (MP Biomedicals, LLC, Solon, OH) with 64 wt.% sulfuric acid at 45°C. The acid was
prepared with 98% sulfuric acid from VWR International (West Chester, PA) and Millipore
filtered water prepared with Direct Q filtering system (Millipore, Billerica, MA). The acid was
mixed with MCC in a beaker at a ratio of 8:1 vol. to wt. and was constantly mechanically stirred
at 50 rpm during the reaction. The acid hydrolysis reaction was stopped after 40 min by a 10-fold
dilution with Millipore filtered water under vigorous agitation. The suspension was then
centrifuged in an Allegra X-30 from Beckman Coulter, Inc (Indianapolis, IN) at 9,000 rpm for 20
min. After centrifugation, the supernatant was separated from the pellet, replaced with fresh
Millipore filtered water and vigorously stirred for a second wash to remove excess acid.
Suspension was centrifuged again, and the resulting pellet was placed in a Spectra/Por 2 dialysis
membrane (Spectrum Laboratories, Inc., Rancho Dominguez, CA) with a 12 – 14 KD MWCO.
Pellet was dialyzed against Millipore filtered water until constant neutral pH (6-7). The ensuing
dialyzed suspension was centrifuged at 9,000 rpm for 10 min to separate the CNC from cellulose
solid residue (CSR). The CNC suspension was lyophilized to a white powder.
6.1.2 CNC/PCL MIXING, MICROFLUIDIZATION, AND OPTIMIZATION OF
SOLUTION PROPERTIES AND SPIN COATING PARAMETERS DURING
FILM FABRICATION
It had to be experimentally determined as to what mixing ratios of polymer solution and CNC
suspension would provide optimal solution properties to enable spin-coating of uniform thin films
containing both materials. To ensure even distribution of CNCs with the final polymer matrix, a
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uniform homogenous solution had to be prepared in which CNCs would remain stable without
rapid sedimentation. To achieve these means, first a volatile solvent capable of rapid evaporation
under spin coating conditions had to be selected to dissolve our polymer – PCL with numberaverage molecular weight of 80,000 Da from Sigma-Aldrich (St. Louis, MO). We selected
Dichloromethane (DCM) 99.5% from VWR (Radnor, PA) based on previous reports of use in
applications to produce polymeric nanofibers (71, 72). Stock solutions were prepared by dissolving
PCL in DCM for 2 hrs. on a wt./vol % basis. These solutions were further mixed with CNC
suspensions prior to spin coating for a final polymer concentration of 10% w/v.
To ensure optimal mixing of CNCs within the polymer solution three factors had to be
resolved. First, a readily volatile solution capable of being miscible with DCM and capable of resuspending lyophilized CNCs without rapid sedimentation had to be selected. This same solution
had to be non-corrosive and capable of being used in an LV-1 microfluidizer, Microfluidics
(Westwood, MA). Microfluidic shearing of CNCs was performed to break apart any aggregates
formed during the lyophilization and re-suspension process. It was with this in mind that the second
factor had to be determined: how many passes through the microfluidizer would ensure the
formation of a homogenous final product when mixed with PCL/DCM. Last, the mixing ratio of
CNC suspension to PCL/DCM capable of producing uniform thin-films under selected spincoating parameters had to be determined.
It is well known that aqueous suspensions of CNC provide optimal dispersibility due to the
polar interaction and hydrogen bond formation of cellulose hydroxyl groups with water molecules.
The following chart in Table (3) reported in work by Okura, et al. was consulted and Ethanol
(EtOH) was selected as an alternative to aqueous re-suspension for the CNC dispersant as it was
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empirically determined in previous work to provide good dispersibility to CNCs in solution and
is a non-corrosive liquid that possesses good miscibility with DCM which water does not.
Table (3): Solvents capable of providing good dispersion of CNCs in solution phase “Adopted”
from (73).

Microfluidization consisted of multiple passes through an LV-1 microfluidizer to ensure
homogenization of the CNC suspension creating a more uniform distribution of particle size. It
was experimentally determined that two sequential passes of CNC (2% wt./vol) in 100% EtOH
from VWR (Radnor, PA) through the microfluidizer was sufficient in meeting the desired criteria
for emulsion.
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Solution properties had to be optimized to meet selected spin-coating parameters. SpinCoating (SC) is the use of high speed centripetal force for the application of coating thin films
evenly across a substrate. This method makes use of the rapid evaporation of a volatile solution
from a liquid state leaving behind a uniform film of micron or nanosized thickness. To ensure films
thick enough for supporting cell culture, we selected the following parameters (Speed: 1500 rpm,
Solution Volume: 750 µL, Time: 60s). The mixing of EtOH and DCM affects properties of solution
volatility resulting in production of non-uniform thin films at certain mixing ratios. Qualitative
experimentation was performed to address this concern. To establish the correct mixing
parameters, solutions of varying ratios were created and then spun-coat onto glass slides to see
which produced the most even and uniform films. Mixing ratios for DCM: EtOH in mL to mL of
5:5,6:4,7:3,8:2,9:1 were used and it was experimentally determined that for the afore-mentioned
SC parameters, a mixing ratio of 9:1 DCM:EtOH would be used as the other mixing ratios resulted
in production with uneven coating or tears within the polymer matrix.
Prior to spin coating, post microfluidized CNC solutions were diluted in 100% EtOH to a
concentration of 1% wt./vol. To fabricate solutions for the varying wt./vol. % CNC, the 1% CNC
suspension was diluted further in the PCL/DCM with the addition of 100% ethanol to maintain the
necessary 9:1 DCM:EtOH vol./vol. mixing ratio of 9:1. See Table (4) below:
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Table (4): Mixing Volumes to create CNC/PCL solutions used for Spin Coating.
Final wt./vol %

Vol. PCL/DCM Sol.

Vol. 100% EtOH

Vol. 1% CNC in

CNC

(mL)

(mL)

EtOH (mL)

0

9

1

0

0.01

9

0.9

0.1

0.02

9

0.8

0.2

0.05

9

0.5

0.5

0.10

9

0

1

For spin coating a G3P spin coater from Specialty Coating Systems (Indianapolis, IN) was
used and operated on the afore mentioned parameters. Glass coverslips (22x22 mm) were placed
on the spin coating chuck cleaned with first acetone, and then ethanol to remove dust.
Polymer/CNC solutions were then deposited on the slide using a glass 1 mL syringe. After
fabrication, films were annealed at 90C for 10s on a silicon wafer using a heating plate in order to
relieve internal material stress generated during the fabrication process.
6.1.3 METHODS OF SURFACE TREATMENT: SURFACE PATTERNING AND
OXYGEN PLASMA SURFACE ACTIVATION
To enhance the hydrophilicity of the film surface, oxygen plasma etching was used to increase
the presence of polar groups on the surface on the film. This was done with the aims of making
the surface more attractive for cellular attachment. Effective time of plasma treatment had to first
be established. Plasma treatment was performed at 50W power with an oxygen flow rate of 10
cc/min using a PE-25 PlasmaEtch oxygen plasma chamber (Carson City, NV) for treatment times
of Sham – 30s – no plasma, 30s, 60s, 180s, and 360s. Effects of plasma treatment were determined
by H2O contact angle (CA) measurements and the treatment time was selected as the time at which
significant reduction in measured CA did not change from the prior time point. These effects were
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assessed via one-way ANOVA followed by Tukey’s HSD post-hoc. CA measurements were
performed using a dataphysics model OCA 15plus goniometer (San Jose, CA) in which a direct
measurement of the tangent angle at the three-phase contact point on a sessile drop profile was
taken (74). After plasma treatment time was selected, CA analysis was performed for all samples
across all CNC concentration ranges. This was done to investigate if CNC concentration had an
effect on resultant CA and/or if effects interacted with plasma treatment condition to produce such
results. Affects were assessed using Two-Way ANOVA.
To introduce patterns on the substrate surface, we utilized a nano-indentation approach using
a flat-patterned and nano-ridged PDMS stamp. Films were first stamped at 90C on a hot plate
using the flat PDMS stamp followed by imprinting with the nano-ridge pattern. This process was
done to promote cellular alignment in response to topographical cues.
6.2

METHODS FOR MATERIAL CHARACTERIZATION OF CNCs

6.2.1 CNC MOLECULAR WEIGHT
To our knowledge this is the first time CNC molecular weight has ever been determined via
molecular weight determination feature of a Zetasizer Nano ZS system. One study has previously
reported the molecular weight of CNC using multi-detector asymmetrical-flow field-flow
fractionation (75). The values used for input parameters of refractive index increment (dn/dc)
0.148, and shape factor (Rg/Rh) 1.75 used in this study were extrapolated for use in our
measurements. Prior to measurements, cuvettes were thoroughly rinsed with both 70% ethanol and
ultrapure water and allowed to dry in an oven at 100° C for 1 hr. to ensure the presence of no
contaminants. Measurements were conducted at 25° C and performed in triplicate. For
measurements, lyophilized samples first re-suspended in ultrapure water at a concentration of 10
mg/mL and then diluted to series of increasing concentrations between 0.25 and 1 mg/mL.
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Immediately prior to insertion into Zetasizer, samples were sonicated for 2 min. A Debye plot was
generated post-measurements, with molecular weight corresponding to the inverse of the yintercept generated through regression modeling.
6.2.2 CNC POLYDISPERSITY BY MICROFLUIDIZATION
Microfluidization was performed on samples to ensure the breakup of aggregates in solution
phase thereby promoting a more even distribution of crystals in the fabricated films. As a means
to validate this, polydispersity (PdI) measurements were performed not only to characterize CNCs
but to validate and characterize synthesis and fabrication process parameters. Using DLS
techniques, measurements were conducted after 1 pass through the microfluidizer, for n= 10
measurements. Prior to measurements, lyophilized CNCs were resuspended at a concentration of
10 mg/mL. Samples were then passed through the microfluidizer and following suspension
shearing were diluted to a series of increasing concentrations between 0.25 and 1 mg/mL. Prior to
measurements, cuvettes were thoroughly rinsed with both 70% ethanol and ultrapure water and
allowed to dry in an oven at 100° C for 1 hr. to ensure the presence of no contaminants.
Measurements were conducted at 25° C. Immediately prior to insertion into Zetasizer, samples
were sonicated for 2 min.
6.2.3 TEM IMAGING OF CNCs
TEM imaging was not only used to characterize particles but was also used to assess effects
of microfluidization on particle size. For TEM sample preparation lyophilized CNCs were
resuspended in ultrapure water at a concentration of 10 mg/mL and subjected to sequential
Microfluidization for up to 3 passes. After each pass an aliquot was taken and diluted to 25 µg/mL,
then sonicated for 2 min and pipetted onto carbon-coated TEM grids (300 mesh, 63 μm grid hole
size). Image analysis and size measurements were performed using ImageJ. Length measurements
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were analyzed using one-way ANOVA, followed by Tukey’s HSD. The number of particles
assessed for each microfluidization step are as follows: (MF 0, n = 23), (MF 1, n = 28), (MF 2, n
= 19), (MF 3, n = 37). Imaging was performed at 100,000x magnification.
6.3

METHODS FOR MATERIAL CHARACTERIZATION OF FILMS

6.3.1 SURFACE ROUGHNESS OF FILMS
For surface roughness measurements, a Keyence VK-X100 3D scanning confocal
microscope (Osaka, Japan) was used at 250x magnification to analyze the surface profile. This
methodology was used to determine if plasma etching had effects on surface roughness. For this
process, five different images were taken per film sample before and after plasma etching, and
results were compared via paired student’s t-test. Roughness before and after plasma was also
compared based on CNC concentration and these effects were analyzed by one-way ANOVA
independently of the pre vs. post plasma condition.
6.3.2 SCANNING ELECTRON MICROSCOPY (SEM) IMAGING AND ELEMENTAL
COMPOSTION ANALYSIS BY ENERGY-DISPERSIVE X-RAY
SPECTROSCOPY (EDX)
SEM imaging was performed in order to validate the imprinting of nano groove-ridge
patterns on the surface of the films. Imaging was performed using a JEOL JEM-1011 scanning
electron microscope (Tokyo, Japan) operated at electron beam strength of 15 kV with attached
camera by Advanced Microscopy Techniques (Woburn, MA). Elemental Composition analysis by
EDX was performed in conjunction with imaging using the same microscope. EDX was performed
with 10 kV electron beam and was done to assess changes in the molecular surface composition
introduced by oxygen plasma treatment. For this process, three different measurements were taken
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per film sample before and after plasma etching, and results were compared via paired student’s ttest.
6.4

METHODS OF FABRICATION OF FILMS USED IN CELL VIABILITY
EXPERIMENTS
Due to size limitations of cell culture plates, films had to fabricated in a slightly different

manner to meet the necessary dimensions for sterile cell culture. Cell studies conducted for
viability were performed in 6-well plates with a culture area of 4 cm2. Films had to be fabricated
in a manner capable of meeting these dimensions and remaining attached to the bottom of the
culture plate in cell culture media. In order to achieve this, sheets of polyethylene terephthalate
were purchases from VWR and A 9/16 in. punch set, and mallet was used to cut out appropriate
size PET substrates onto which PCL films were then spun coat. To spin coat these samples, PET
substrates were attached to glass coverslips via double sided sticky tape, and then PCL were spun
coat onto their surface using the same protocol as mentioned in section 7.2. After annealing the
samples, film-covered PET substrates were removed using a razor blade and attached to the bottom
of culture plates using double-sided sticky tape.
6.5

METHODS FOR HARVEST, CULTURE, VIABILITY ASSESSMENT,
IMMUNOFLUORESCENT IMAGING, AND IMAGING STUDIES OF
CARDIOMYOCYTES ON FABRICATED FILMS
The animal use protocol used in this study was approved by the University of Arkansas,

Institutional Animal Use & Care Committee (# 17061). Cardiomyocytes were isolated by the same
procedure listed in SA 1. Films used in cell imaging were fabricated in same manner as described
in section 7.2. Prior to seeding of cells, films were sterilized in 70% EtOH overnight and then
washed 3x with PBS. Films for imaging were then transferred to sterile 6 well plates allowed to
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dry for 4 hrs. under UV light in a cell culture hood. Films for cell viability were left in the same
plates but given same sterilization treatment for use in the subsequent culture and experiments.
Cells were plated at a seeding density of either 1.2 million/cells for 6-well plates containing the
film-covered coverslips, or 533,000 cells/well for 12 well plates containing the attached filmcovered PET substrates. Cells were cultured in a humidified incubator at 37° C, and 5% CO2. On
Day 2 post-isolation, non-viable cells were removed from cell populations by washing with PBS,
followed by media change of 10% FBS. On Day 3 post-isolation media was changed to 2% FBS,
followed by one further changes every 2-3 days until experiments were conducted. Cells were
cultured in 3 mL working media for 6-well plate and 2 mL for 12-well plates.
For viability testing , media was changed and replaced with 833 uL of fresh media per well
and then the MTS dye 167 mL was added. This is in line with manufacturer’s recommended
protocol of keeping a ratio of culture media to MTS dye at 5:1. Tests were performed in triplicate,
with n=3 per scaffold condition. Cells were incubated with the MTS dye for 4 hr. at 37° C, and
5% CO2. Absorbance readings of the reduced MTS tetrazolium salt were conducted immediately
thereafter as previously mentioned under SA 1. Magnitude of absorbance was directly correlated
to number of viable cells on a given scaffold. Viability was assessed by both CNC concentration
and patterning effect. Results were analyzed using a two-way ANOVA.
For immunocytochemistry and immunofluorescent imaging of cells on scaffolds, the films
containing cells were removed from 6-well plates and fixed using 4% paraformaldehyde in PBS,
followed by addition of a permeabilization and blocking buffer consisting of 2% FBS v/v, 2%
BSA v/v, and 0.1% v/v of Triton X-100 in order to prevent non-specific binding of antibodies.
Cells were then treated with primary antibody anti-sarcomeric alpha-actinin at a dilution of 250x
followed by secondary antibody and AlexaFluor® 488 conjugated goat anti-mouse IgG at a
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dilution of 200x. Cells were cross-stained with DAPI at a dilution of 5000x in order to determine
homogeneity of myocytes with the population. After cell fixation, coverslips were mounted on
glass slides, and immunofluorescent Imaging was carried out using a Zeiss Imager M.1 microscope
at 63x magnification with fluorescent filters. Images were captured using the Zeiss Axiovision
software.
For cell functionality assessment, two parameters were used to characterize cardiomyocyte
performance by scaffold condition. (1) Cardiomyocyte contraction rate was determined as beats
per minute in which 3 videos were taken using a Zeiss Axiovert Inverted Light Microscope with
attached AMT V602 camera and image capture engine software (Woburn, MA). For each scaffold
conditions, videos were captured in 3 different areas at a magnification of 40x. Recordings were
conducted for 60s and cell contractions within that time frame were reported. (2) Inverse Aspect
ratio (AR-1) or length/width was calculated for cells cultured on nan-patterned scaffolds. This was
done to see CNC concentration within the nanopatterned films had effects on cell alignment and
orientation. Immunofluorescent samples were prepared by previously listed protocol and imaging
was carried out using a Zeiss Imager M.1 microscope at 63x magnification with fluorescent filters.
Images were captured using the Zeiss Axiovision software, and post-processed using ImageJ to
determine length and width measurements. Length is reported as the longest detectable point-topoint distance under immunofluorescent analysis. Width is determined as the widest detectable
point ~ typically reported as diameter of cell nucleus observed under cross-stained DAPI imaging.
7

RESULTS OF CNC CHARACTERIZATION
As previously mentioned, to my knowledge this is the first time molecular weight of CNCs

has ever been determined via the modality of DLS molecular weight determination. A previous
study (75) reported the molecular weight of CNCs as determined by multi-detector asymmetrical-
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flow field-flow fractionation to be ~ 107 Daltons. Using our method, we report the molecular
weight to be ~ 1.86 x 107. For simple understanding of the Debye theory, it is generally assumed
that with increasing concentration of particles within a solution, the molecular weight determined
by DLS will increase due to aggregation within the colloidal system. A range of data points is
generated for increasing concentration ranges, and then a linear fit is applied for whose y intercept
can be extrapolated as the inverse of molecular weight. Our data follows this model with an R2
value of 0.858 indicating a decent fit. This is shown in Figure (25).

Debye Plot of CNC in ddH20
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Figure (25): Debye plot for determination of CNC molecular weight. Datapoints are from n=3
measurements, and 1/y-intercept corresponds to molecular weight determined from linear
regression modeling with R2 coefficient of 0.858.
It was important to characterize the effects of microfluidization on the CNC samples in
order to validate the break-up of aggregates by this process. This was characterized for the same
concentrations used in molecular weight analysis for 1 pass through the microfluidizer. Although
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it was not characterized statistically, it can be seen in Figure (26) that this process greatly reduced
the polydispersity of CNC suspensions at all concentrations and created more homogenous
solutions with much lower PdI for all concentrations. Shown in Figure (26).

DLS determination of PdI as a
function of Microfluidization Step
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Figure (26): Polydispersity of CNC characterized for 1 pass through microfluidizer. Range of
concentrations corresponds the same ones used in molecular weight measurements.
Image analysis was performed via TEM to assess crystal size. A representative image of
CNCs is shown in Figure (27) with size results presented in a MATLAB generated Figure (28).
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Size results shown below Figure (28) were
determined via ImageJ and assessed using a oneway ANOVA, with all sequential microfluidization
steps resulting in significant decrease in size with p
< 0.001 as compared to the non-microfluidized
CNCs.
Figure (27) - left TEM image of CNCs after 2
passes through microfluidizer at 100,000x
magnification.

Figure (28): CNC size analysis using ImageJ and MATLAB to process TEM images and
characterized for up to 3 sequential passes through microfluidizer. Here, * p < 0.001.
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8.1

RESULTS FOR FILM CHARACTERIZATION
PLASMA TREATMENT, H2O CA, AND SURFACE ENERGY

50W O2 Plasma Effects on PCL H2O CA
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Figure (29): Selection of oxygen plasma treatment time to be used for film development.
Effective treatment time selected as 180s.
To initially select the time of plasma treatment for film development, PCL films were
subjected to increasing times of oxygen plasma, and effective treatment time was selected at
which significant reduction in water contact angle on the surface of the film from the prior
time point did not occur. Significant difference was assessed via one-way ANOVA, and sig.
reduction did not occur, p > 0.05 between 180-360s treatment time. Tukey HSD post-hoc was
used to determine this difference and a critical where calculated value of p > 0.05 was observed.
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Results are shown in Figure (29) with red circle indicating the point at which significant
reduction in film wettability did not occur.

***, p < 0.001

CNC wt. %

Figure (30): Effects of plasma on film surfaces by CNC concentration assessed by two-way
ANOVA. Plasma effects on CA significant across all CNC concentrations at p < 0.001. CNC
concentration not significant for determining CA.
The effects of plasma etching in conjunction with CNC concentration were investigated
analyze the effects of hydrophilicity on the surface of the film. These effects were analyzed via
two-way ANOVA and pairwise comparisons evaluated using Tukey’s HSD post-hoc for twofactor ANOVA. The results showed a significant decrease in film hydrophilicity based on plasma
condition for treatment condition, p < 0.001 but did not a show any significant effects by CNC
concentration. Analysis was performed for significance level α = 0.05

55

8.2

SURFACE ROUGHNESS

A

B

Figure (31): Surface Roughness profiles as captured by Keyence Confocal Light Scanning
Microscope. (A): Flat-pattern PCL film, (B): Nanopatterned PCL film – groove-ridge indentation
pattern can be observed.
Film roughness was characterized using a Keyence scanning confocal light microscope – credit
to Nanomechanics and Tribology Lab and was used to assess surface profiles for roughness
determination. The results of this characterization approach were compared for to analyze effects
from both CNC concentration, and plasma treatment effect. Plasma treatment effects were
analyzed independently for each CNC film sample using a paired student’s t-test, α = 0.05, to
compare the before and after effects of plasma etching. Effects of surface roughness were
compared independently for all nanopatterned films by CNC concentration, and were assessed via
one-way ANOVA both before and after plasma treatment and were followed by Tukey’s HSD
post-hoc test. Results showed that increasing CNC concentration at the highest wt. % used in this
study – 0.10% resulted in significant increase at p < 0.05, of surface roughness for both pre and
post treatment film samples. These results are presented in Figure (32) below.
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Effects of Plasma Tx. on Film Roughness
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Figure (32): Effects of plasma treatment on film roughness by CNC concentration. Paired
student’s t-test used to assess pre/post effects by film condition, p > 0.05, for all conditions. Oneway ANOVA used to independently assess pre/post treatment CNC effects for nanopatterned films
on surface roughness. p < 0.05 between 0.10 % CNC and PCL nanopattern ctrl for both pre and
post plasma treated films.
8.3

SEM IMAGING AND EDX ELEMENTAL COMPOSITION ANALYSIS
Scanning Electron Microscopy was used to image patterning effects on film samples, and to

qualitatively assess whether any damage to film patterns occurred as a result of plasma treatment.
SEM imaging was performed at 10,000 with a 15-kV e- beam. As can be seen in Figure (33) no
detectable damage was observed. SEM imaging was also performed to measure film thickness.
For this, a plasma treated flat-pattern PCL film was mounted sideways in SEM vacuum chamber
on glass slide. Measurements were taken n=10, from surface of glass slide until detectable contrast
change in image was observed. The values were averaged, and average resultant film thickness
generated from spin coating parameters and surface treatment effects was determined to be 13.55
µm. This image was captured at 1000x magnification using a 10-kV e- beam and is shown in
Figure (34) below.
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Figure (33): Representative SEM image of nanopatterned film sample. Film sample shown here
is 0.05% CNC captured at ~ 10,000x magnification with 15 kV e- beam.

Figure (34): Representative SEM image of flat-patterned PCL film sample (side-view) used for
thickness measurements. Image was captured at 1000x magnification with a 10.0 kV e- beam.
Thickness was determined to be 13.55 µm for n = 10 measurements.
The last characterization performed using SEM techniques was elemental composition
analysis as a result of plasma treatment using energy-dispersive x-ray spectroscopy (EDX). This
characterization technique allowed us to assess how the plasma treatment affected the surface of
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the films on the molecular level. Plasma effects for the elements of carbon and oxygen were
compared for pre-post treatment film composition using paired student’s t-test, and were shown to
significantly decrease, and significantly increase the amount of carbon and oxygen at p < 0.001
respectively. These results are corroborated with previous results showing enhanced wettability
after plasma treatment.

Figure (35): Oxygen plasma treatment altered surface composition of films, thereby increasing
presence of hydrophilic reactive groups on surface of films and increasing overall oxygen atomic
composition.
9

RESULTS OF IMMUNOFLUORESCENT IMAGING, CELL VIABILITY BY
SCAFFOLD CONDITION, AND FUNCTIONAL CHARACTERIZATION OF
CARDIOMYOCYTES
Immunofluorescent Imaging of cells seeded on nanopatterned films, Figure (37) showed

superior cell alignment provided by the nanotopographical cues induced by film patterning. This
was seen across all CNC conditions for plasma-treated nanopatterned films. Cell inverse aspect
ratios were calculated for each CNC concentration and shown in Figure (38).
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A

B

Figure (36): Cell response can be observed based on film-patterning. (A): Cells cultured on flatpattern 0.01% CNC film show random attachment. (B): Cells cultured on 0.01% CNC
nanopatterned film show topographical response promoting alignment and organized spreading
patterns.

Inverse Aspect Ratio by CNC Concentration
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Figure (37): Inverse aspect ratios as a function of CNC concentration. Cells exhibited more
elongated shapes on 0.1% CNCs films, with a general trend of increasing cell elongation with
increasing CNC concentration. Results not assessed statistically.
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Figure (38): Cells cultured on nanopatterned films showed enhanced electrical coordination and
electrical activity. p < 0.001, averaged across n=3 for all CNC concentrations.
Physiological performance of cells by scaffold condition was averaged across all CNC
concentrations for nanopatterned and flat-patterned films to examine patterning effects on cell
behavior. These results were assessed via student’s t-test and resulted in significant enhanced
electrical coordination and electrical activity with the formation of synchronized beating
syncytium of cells on nanopatterned films. Overall beats per minute was significantly greater for
nanopatterned films with p < 0.001.
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Figure (39): Viability of cells on plasma treated films by patterning effect and CNC concentration,
n=3 for each. Cells cultured on films containing CNC were all slightly more viable than ctrl
excluding CNC 0.02% for both flat and nanopatterned samples. Patterning effects for each CNC
concentration were assessed by student t-test, and CNC concentration affects by patterning
condition were assessed via one-way ANOVA. Significance was not observed in either case.
The last characterization of cell effects determined was cellular viability by scaffold
condition and was assessed via two-way ANOVA with two-factor Tukey HSD post-hoc. Results
were determined to be non-significant for both patterning effects and CNC concentration, although
cells cultured on nanopatterned films showed slightly better viability than those culture on PCL
flat-patterned films, with the exception of 0.02% CNC.
10 DISCUSSION AND CONCLUSION
10.1 SPECIFIC AIM 1
The results generated from this Thesis work for Specific Aim 1, show PEGylated gold
nanoparticles possess promise as a safe platform for potential for use in stem cell therapy to the
myocardium due to no reductions in cell viability observed for any of the particle concentrations
relative to the control. This preliminary toxicological analysis will serve as a secure foundation
upon which other toxicity studies will be conducted.
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Prior to assessing the effects imparted on cardiomyocyte cells by these particles, it was
necessary to produce particles that met certain design criteria. Synthesis protocols needed to be
capable of ensuring particles were produced uniformly with good control over size, shape, and
surface characteristics. Synthesis procedures also needed to be capable of preventing particle
aggregation. Aggregation of nanoparticles within biological systems may greatly affect their
physicochemical properties, thereby affecting the intended outcome. Aggregation reduces
available surface area within colloidal systems, and reduces the reactivity, transport kinetics and
bioavailability of nanoparticles (76). Results generated from particles in an aggregated state may
not accurately reflect the true effects of GNPs on cell viability when in uniform colloidal
dispersions. The methodologies used to characterize the particles in this work helped us to
determine if our synthesis procedures had allowed us to ensure the dampening of these possible
effects.
Data relative to the synthesis protocols is shown in Figure (8), and Table (2). This data
suggests that measurements of GNP cores in a post-pegylated state may more accurately reflect
the true dimensions of particle size, as aggregation prevents accurate measurements from being
performed. As can be noted in Table (2) the sample size for particles used in measurement
comparisons was much higher for PEGylated GNPs. The larger sample sizes available for
PEGylated GNPs is a direct result of even distribution of PEGylated GNPs is observed during
imaging presenting a more accurate indicator of the true nanoparticle population sizes. The results
of Figure (8) can be explained by the narrow variance calculated for the sample at each condition
and the unequal sample sized between pre and post PEG states. I believe that if a greater sample
size were to be used for the 5 nm citrate-GNPs these incongruencies would not occur and a
significant difference in particle size by TEM analysis would not be observed.
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The size data for the pre-PEG gold is slightly higher than the calculated TEM particle
diameters for both pre and post PEGylated GNP cores and can be explained by the inclusion of
the citrate layer in the hydrodynamic diameter calculations. DLS size data also serves to validate
the presence of the PEG ligand presence on the nanoparticle surface with effective hydrodynamic
diameter of PEG chain attachment increasing to 30.85 nm for the 18 nm GNP core, and 34.00 nm
for the 25 nm GNP core. It should be noted that DLS measurements were performed immediately
following synthesis and PEGylation without further washing, and thus the low concentration of
the 5 nm sample was below the manufacturer recommendations for particles less than 10 nm in
size (59). 0.167 mM equivalates to 0.033 mg/mL and is well below the necessary min.
concentration of 0.5 mg/mL in this size range. The effort to produce size results for the 5 nm
particles resulted in highly erroneous data so instead, UV-Vis characterization was used to validate
the presence of PEG attachment on these particles. Comparative analysis of PEGylation state size
for DLS was performed using a two-tailed student’s t-test assuming equal variance with a sig. level
of α = 0.05. For the 18 nm particles, p < 0.001, and for 25 nm particles p < 0.001.
For understanding of the zeta potential data: the magnitude of the zeta potential gives an
indication of the stability of particles within a solution with potentials greater than +30 mV or
more negative than -30 mV normally considered stable. If all particles have the same net charge
either (+) or (-) they will tend to all repel each other without the occurrence of aggregation (60). If
the particles possess low zeta potentials values, i.e. between -30 and +30 mV then there will be no
force to prevent the particles coming together and aggregating under the influence of van der Waals
interactions. This can be clearly observed for the data we present regarding the PEGylated particles
for both the 18 and 25 nm samples in Table (2). However, for spherical nanoparticles, particle
interaction effects are governed not only by van der Waal attraction but by electrostatic repulsion.
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PEG attachment to a particle is capable of mitigating both of these by decreasing the surface energy
of the particle (61-63). PEG decreases the amount of interparticle attraction by increasing the
hydrophilicity of the particles via forming hydrogen bonds with the solvent (61). This increased
interparticle distance by due to steric hindrance and solvent interaction thereby helps to stabilizes
the particles within a colloidal system. Although the zeta potentials for both the 18, and 25 nm
particles decreased from ~ 30 mV to ~ 4 m.5 mV, it can be assumed that due to the shielding
effects imparted by PEG attachment the particles were stable in solution phase.
Lastly, for spectrophotometric assessment: spectrophotometry is the quantification of the
reflection or transmission properties of light through a medium or material given as a function of
the light’s wavelength. Gold nanoparticles exhibit a very signature measurement profile when
characterized by this technique with max. absorbance wavelength in the region of 500-550 nm
dependent on particle size. This effect can be explained due to the plasmonic properties of GNPs.
When specific wavelengths of light interact with gold nanoparticles, and due to the properties of
localized surface plasmon resonance (SPR), collective oscillation of the electrons in the outer
conduction band of gold atoms occurs resulting in strong extinction of the light (absorption and
scattering) (65, 66). The size of gold nanoparticles greatly effects the response of the (SPR) effect
resulting in absorbance at longer wavelengths with increasing nanoparticle size. Concentration of
a material, in our case concentration of gold within a colloidal system determines the magnitude
of relative absorbance, with higher concentrations of particles absorbing more light. PEGylation
alters the absorption properties of GNPs with increase in particle size. This can be seen in Figure
(12) for each particle species with a red-shift for max. absorption occurring at longer wavelengths
with reported values for each spectrum located in Table (2). The shift in the absorbance spectrum
also serves as means to validate the attachment of PEG to the 5 nm nanoparticle surface.

65

The results from viability analysis of concentration effects provide a potential dosing
recommendation, 1 nM, at which delivery therapy might be best effective and provide the least
damage to the myocardium. The same goes for size analysis as to which size nanoparticle may be
most effective for inducing the least damage to the myocardium under delivery conditions. It is
promising that the 25 nm particle size showed the greatest cell viability as compared to the other
sizes and control. With increasing particle diameter, reactive surface area also increases thereby
making it possible to conjugate more ligands with bioactive qualities. The increase in size will
allow more potential uses during particle design, i.e. the conjugation of both targeting and stem
cell binding ligands due to the increased available surface area. The data in both cases were not
always distributed normally. It was due to this that both parametric and non-parametric methods
were used to evaluate the resulting magnitude of differences. In both cases, non-parametric
methods showed increased statistical significances with lower p-values for all post-hoc
comparisons. It is given this that I would conclude that for future evaluation of toxicity studies,
non-parametric methods should be used when assessing toxicity effects especially if sensitivity is
key.
10.2 SPECIFIC AIM 2
Results from SA 2 show cellulose nanocrystals as a good composite material for developing
polymer blend platforms for cardiomyocyte cell culture in-vitro, and the patterning effects used in
fabricating the films used in this study were an effective means of creating conditions favorable
for both cell adhesion and alignment, as well as overall cardiomyocyte culture.
Characterization of the CNCs in solution phase was first very important in order to promote
uniform distribution of the crystals within the films after spin coating. Due to the investigations of
the effects of microfluidization on the size, and polydispersity of the CNCs, and be assumed that
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this technique was capable of sufficiently breaking up any particle aggregates, and thereby creating
a more homogenous CNC dispersion. The results in both Figures (26) and (27) lead us to conclude
exactly this. The effects of microfluidization on CNC PdI were not assessed statistically but were
shown to create a large decrease in PdI for each concentration range tested. If the CNCs had been
subjected to further microfluidization steps, it is likely that even a further decrease in PdI would
have occurred. Microfluidization effects on CNC size were characterized for up to 3 passes
followed by TEM imaging analysis. The reason we used TEM instead of DLS was because in
conjunction with determining size effects, we wanted to visualize the orientation, and decreased
aggregative effects induced by microfluidization. As you can see in Figure (27) the particles are
spread out across the image field with limited amounts of aggregation after two passes through the
microfluidizer. The size effects were assessed by one-way ANOVA, and only showed significant
differences when compared to the control. Each subsequent microfluidzation step was not
significantly different in size to any prior step. This leads us to conclude that the shearing forces
exerted by high pressure homogenization affected particle aggregation more than individual
particle size. The large size calculated for MF= 0 was done for TEM imaging in which individual
particles could not be distinguished and larger aggregates were mistakenly assumed to be
individual particles.
Results from characterization of film fabrication allowed us to determine if the effects of
surface treatment, and patterning were capable of promoting cellular attachment and adhesion. For
this characterization, it was first assessed as to how surface oxygen plasma treatment would induce
hydrophilic properties on the film surface, and if CNCs would also interact to promote these
effects. More hydrophilic surfaces possessing high surface energy will result in even spreading of
water due to increased presence of polar groups on the surface capable of forming hydrogen bonds
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with molecules in the water. Oxygen plasma treatment induces these effects and was used
primarily for this first: creating a more hydrophilic surface that would be favorable for cell
adhesion. The results of this characterization are shown in Figure (30) and were significant across
films at each CNC concentration with p < 0.001. The effects of CNC on film hydrophilic were
shown to be non-significant. Figure (35) also shows the results of plasma treatment, with EDX
data showing an overall increase for O2 on the film surfaces indicating the induction of oxygencontaining reactive as a result of plasma treatment. This was significant as averaged across all
CNC concentrations at p < 0.001 between the pre and post-treated states.
It was hypothesized that with increasing CNC concentrations, film roughness may also
increase and promote more favorable surface structure for cell attachment. These effects were not
as pronounced as initially hypothesized with only the highest CNC concentration exerting such
effects. 0.10 wt. % CNC created surface conditions that were rougher than the control at the level
of p < 0.05. Also, it was seen that plasma effects were non-significant in increasing surface
roughness as well.
The nanotopographical response of cultured cells to form aligned structures shows that film
patterning had the intended effects. Images taken showed superior cell alignment and organization
on the nano-patterened films. The analysis of physiological cardiomyocyte function by patterning
condition also shows that imprinted CNC-PCL scaffolds are a good platform for developing
culture conditions to simulate in-vivo cardiomyocyte physiology, as the cells cultured on these
films showed superior contractility and electrical coordination. The technology regarding CNC
suspension, and polymer solvent miscibility through spin-coating will prove effective when
transitioning into the development of porous mesh scaffolds composed of PCL:CNC blended
nanofibers by means of Rotary Jet Spinning.
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11 LIMITATIONS
Each respective specific aim had certain limitations that were not addressed in this study. First,
when elucidating mechanisms of toxicity, it is important to understand the molecular affects, i.e.
upregulation or downregulation of certain biomolecule signaling patterns that govern such cell
behavior. This study did not address such objectives, as we were more interested in understanding
the nanoparticle properties that could exert such affects. It will be important in future work to add
gene/protein expression studies to better elucidate why PEG-GNPs all promoted better viability
for all sized and concentrations as compared to the control.
It is well known that cardiomyocytes possess poor regenerative potential – less than 1%
cellular turnover rate per year. These affects could have led to misinterpretation of our data, i.e.
the particles potentially may have exerted no influence and the result of increased viability is due
to division of non-myocytes within cell populations. If such a thing did occur, it could be concluded
that the particles did still exert effects on cell viability but imparted effects more so on nonmyogenic cells. In order to better investigate this, first flow-cytometric and cell sorting techniques
need to be used to determine percentages of cells within a population. This can be done by tagging
cells expressing biomarkers indicative of a certain cell type and then sorting them into different
cultures likewise i.e. myocyte, fibroblast, endothelial, etc. Conducting a toxicity study of the
particles on each individual type of cell population would allow you to directly compare such
results.
Certain limitations in regard to specific aim 2 would be related to assessment of further
material properties that could have promoted such cellular responses based on film conditions.
First, mechanical properties such as tensile strength and young’s modulus were not addressed a
factor affecting cell performance. These properties would be directly related to increasing CNC
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concentration, and could be further elucidated through investigation of film mechanical properties
by both uniaxial and biaxial tensile characterization. A study such as biaxial characterization of
the films to simulate both the transverse and longitudinal strains experienced by myocardial tissue
during contraction would provide better data to see how material and cultured cells would respond
after simulation of physiologic conditions. If an intended use of these platforms would be related
to use in vivo, or for inducing cardiomyogenic differentiation of stem cells, cells cultured on these
films could be subjected to biaxial stretching and then characterized to see if such mechanical
effects promoted this type of differentiation.
More robust functional characterization of cellular response would also prove effective in
establishing these films as a good culture platform. Electrical force generation and depolarization
wave profile were not measured in this study and could be done through methods of patchclamping. Depolarization profile and conduction velocity assessment of cultured cells would allow
determination of how the affects of material properties created good conditions to promote tissue
formation similar to that of the in-vivo myocardium. Lastly, production of electrically conductive
materials by the same methods used to fabricate films used in this study would be an interesting
area of research for use in cardiomyocyte culture.

12 FUTURE DIRECTIONS
There is much work that will need to be done before a clinically applicable nanoparticle stem
cell delivery system can be developed. The immediate future direction of this work will involve
the creation of an in-vitro perfusion bioreactor system for simulating myocardial ischemia and
reperfusion in-vitro. The transition from a solid barrier culture model to a porous fibrous platform
is crucial for use within the bioreactor system that will be developed. The technology produced in
SA 2, will be transitioned into the process of RJS to fabricate porous nanofibrous scaffolds for
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application within the perfusion chamber. RJS provides an alternative to electrospinning
techniques through utilization of centrifugal forces to eject a thin polymer solution jet through an
orifice and, upon solvent evaporation, the production of nanofiber strands (77). This type of
scaffolding platform will enhance the simulation of an in-vitro testing system to assess the
applicability of nanoparticle cell delivery platforms in regard to homing, cellular engraftment, and
retention. Studies will be conducted to assess these parameters in the in-vitro model. Given
promising results, live animal models will be developed with the hope of one-day developing a
clinically feasible platform.
The next step in toxicological assessment will be to determine toxicity effects of the
PEGylated GNPs on the selected stem cells to be used in this application. It will also be important
to see if these nanoparticles have effects on stem cell differentiation, i.e. if stem cell responses to
PEG-GNPs can induce cardiomyogenic differentiation it would be an added plus to the already
established intended applications. In conjunction with this, a comprehensive literature review will
be conducted to determine ligands suitable for targeting the ischemic myocardium and binding
stem cell receptors. Studies will then be conducted to assess the efficacy of binding on both the
nanoparticle surface and for ligand-receptor interactions. Once such interactions can be validated,
studies will be conducted to assess the efficacy of the overall platform by 1st culturing
cardiomyocytes in the ischemia/reperfusion chamber, 2nd creating hypoxic conditions, and 3rd
determining if stem cell-GNP platform is capable of targeting the cultured cells during the
reperfusion phase of the study. Modalities on how to characterize this will have to be determined.
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